Median durations of response in the overall population were 5.7 months in the combination arm and 4.2 months in the monotherapy arm. Compared with patients receiving cetuximab alone, the cetuximab/irinotecan patients experienced a significantly longer median time to disease progression.
Continue reading " Treating Colorectal Cancer: TREATMENT part 3 "
Capecitabine. An alternative strategy to modulating 5-FU-based chemotherapy has been established through the development of oral fluoropyrimidine analogues. Capecit-abine (Xeloda, Roche), a fluoropyrimidine carbamate with antineoplastic activity, is an orally administered systemic prodrug of 5′-deoxy-5-fluorouridine, which is converted in the body to 5-FU.
Continue reading " Treating Colorectal Cancer: TREATMENT part 2 "
Surgery for Colon Cancer Surgical removal of the involved segment of colon (colec-tomy), along with its blood supply and regional lymph nodes, is the primary therapy for colon cancer. The conventional and accepted treatment for curative resection of colon cancer is laparotomy with hemicolectomy for right-sided or left-sided lesions . The technique of colon resection [...]
A study was conducted to investigate the prognostic factors for colorectal cancer patients in order to improve future treat-ment. Patients who had undergone curative resection (n = 842) were divided into three groups according to age: young (40 years or younger), middle-aged (41 to 64 years), and older (65 years or above). Univariate survival and [...]
Continue reading " Treating Colorectal Cancer: PROGNOSTIC FACTORS "
INTRODUCTION Colorectal cancer is a significant contributor to morbidity and mortality in the U.S., making this disease the second leading cause of cancer deaths overall. In 2002, more than 56,000 lining of the bowel. Some become malignant over time. Most evidence suggests that adenomas are precursors for a substantial proportion of colorectal cancers. This has [...]
